Trial · NCT06422975
Registry of Patients in Shock Treated With Vasopressin
NCT06422975, Unknown, Hospital Universitario 12 de Octubre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Registry of Patients in Shock Treated With Vasopressin. Trials, record NCT06422975. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06422975
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Registry of Patients in Shock Treated With Vasopressin
- NCT number
- NCT06422975
- Status
- Unknown
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Hospital Universitario 12 de Octubre
- Conditions
- Vasopressin Causing Adverse Effects in Therapeutic Use, Shock, Vasopressor Adverse Reaction, Vasopressin Deficiency
- Interventions
- Vasopressin
- First posted
- 2024-05-21
- Last updated
- 2024-07-15
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Characterise the clinical practice of vasopressin use in the context of shock in a multicentre observational study. | 90 days | Describing the time sequence of vasopressin and/or noradrenaline use (what is initiated first) during shock |
| Secondary | Assess what prompted the decision to initiate AVP | Up to 7 days | Assess what prompted the decision to initiate AVP: type of shock (vasoplegic, hypovolemic,...), perfusion parameters (as lactate) or noradrenaline dose (microgram/kg/minute) |
| Secondary | Define the impact of starting AVP on noradrenaline dose | Up to 7 days | Define the impact of starting AVP on noradrenaline dose (microgram/kg/minute) |
| Secondary | Define the impact of starting AVP on lactate level | Up to 7 days | Define the impact of starting AVP on lactate level (mmol/L) |
| Secondary | Observe when AVP is discontinued and how | Up to 7 days | Describe number of participants what AVP is discontinued first and how (abruptly or progressively) |
| Secondary | Estimate the range of doses of AVP used | Up to 7 days | Estimate the range of doses of AVP used and the maximum dose used in routine clinical practice. |
| Secondary | Incidence of side effects | Up to 7 days | Describe the incidence of side effects, whether it is related to AVP dose and patients' comorbidities. |
| Secondary | 28-day all-cause mortality | 28 days | Death on or before study day 28 |
| Secondary | 90-day all-cause mortality | 90 days | Death on or before study day 90 |
| Secondary | Incidence of new renal replacement therapy | From onset of shock until hospital discharge, an average of 2 weeks | New receipt of renal replacement therapy after onset of shock |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06422975
GET https://conductscience.org/api/trials/v1/NCT06422975/registered